RecruitingNCT05903430
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy
Sponsor
The Christie NHS Foundation Trust
Enrollment
60 participants
Start Date
Aug 29, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- Have no MRI contra-indications.
- Eligible for abdominal SABR in accordance with the NHSE SABR Consortium Guidelines or eligible for central lung SABR in accordance with RTOG Guidelines.
- Be able to give informed consent.
- Anticipated life-expectancy \> 6 months.
- Not more than 3 oligmetastatic sites treated in total per patients.
- Performance status ≤ 2.
- Willing to attend follow-up and have details collected on prospective basis for a minimum of 1 year.
Exclusion Criteria5
- Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
- Unable to tolerate MRI scans.
- Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator make it undesirable for the patient to participate in the study.
- Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make it undesirable for the patient to participate in the study.
- Any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05903430
Related Trials
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
Empathic Communication Skills (ECS) Training
NCT0545684112 locations
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667100 locations